Moreover, a synergistic interaction between SGK3-PROTAC1 and BYL719 was demonstrated by CCK-8 assay, suggesting that SGK3 inhibitors should be promising treatment strategies for breast cancer patients who had developed resistance to alpelisib. Here, SGK3 is linked to breast carcinoma.